Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...
Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...
US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...
Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...
New research highlights a critical link between antibodies produced against Epstein-Barr virus (EBV) and the development of ...
The findings, led by researchers from the Institute of Modern Physics (IMP) of the Chinese Academy of Sciences and their ...